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damage, eye and kidney disease). In
1953, the case was reported of a
woman with Type 1 diabetes, whose
diabetic eye disease (retinopathy)
regressed after she developed failure
of the pituitary gland. This led to a
medical procedure most popular in
the 1960s: the pituitary gland was
destroyed to treat advancing diabetic
retinopathy. Although effective,
pituitary destruction was associated
with loss of life, and has been
replaced by laser therapy direct to
the eye.
People with Type 1 diabetes and GH
deficiency do have lower rates of
retinopathy. This points to the role
of GH in the development of diabetic
complications. However, this remains
a controversial area – many other
growth factors have also been
implicated in the development of
complications. GH replacement
therapy does not lead to an
increased incidence of retinopathy in
GH-deficient people with or without
diabetes.
Potential for prevention
Given this background, it is perhaps
surprising that GH is being
considered as a potential factor in
the prevention or treatment of 
Type 2 diabetes. While excess GH
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Despite major fluctuations in supply and demand,
sophisticated mechanisms in the body maintain levels 
of blood sugar (glucose) within narrow limits. Although
under normal conditions, insulin is the major regulator 
of blood glucose levels, growth hormone (GH) and 
insulin-like growth factor-1 (IGF-1) play an important
contributory role. Both of these hormones have potent
effects on glucose metabolism which may be utilized in
diabetes management. Richard Holt explains the growing
interest in exploiting the effects of GH and IGF-1 for people
with diabetes.
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Growth hormone is secreted by the
pituitary gland, a tiny organ in the
centre of the human head just
beneath the brain.This hormone has
major effects on glucose metabolism
– the opposite to those of insulin. It
increases glucose concentrations in
the blood and decreases the body's
sensitivity to insulin, thus opposing
the normal action of insulin. GH
concentrations are up to 2-3 times
higher in people with diabetes
compared to people without the
condition.The excessive GH
secretion may be partly responsible
for the 'dawn phenomenon' – a
rise of blood glucose concentrations
in the early morning before waking
from sleep.
Complications
GH may also be involved in the
development of microvascular
diabetic complications (nerve
( )
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secretion causes diabetes in up to
40% of people with tumours which
over-produce GH (a condition called
acromegaly) , a lack of GH also has a
detrimental effect on sensitivity to
insulin. GH deficiency in adults is
associated with a reduction in muscle
mass and an increase in fat mass,
particularly around the abdomen.
This accumulation of abdomen fat
appears to be important in the
development of insulin insensitivity
(see Ramachandran A. Identifying the
risk factors: diabetes in Asian Indians.
Diabetes Voice special issue –
prevention, June 2003).
Observation of the effects of GH
replacement therapy has helped our
understanding of the role of GH in
glucose metabolism. In the short
term, there is an increase in insulin
insensitivity. However, as lean body
mass (muscle) increases and fat mass
is reduced, long-term insulin
sensitivity gradually improves.
GH administered to
abdominally obese
men led to a reduction
in abdominal fat and
insulin insensitivity.
Metabolic syndrome is a cluster of
features including abdominal obesity,
high blood pressure (hypertension),
insulin insensitivity, and glucose
intolerance – precursors to Type 2
diabetes.There are similarities in the
clinical features of metabolic
syndrome and untreated GH
deficiency.They suggest that the
reduction in GH concentrations seen
in abdominal obesity may be
important in the development of
metabolic syndrome.The correction
of GH concentrations may have
beneficial effects: when GH was
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administered to abdominally obese
men, it led to a reduction in
abdominal fat, and a reduction in
insulin insensistivity.1
Although these results are
encouraging, further clinical trials are
needed to assess the effects of GH
on the incidence of Type 2 diabetes
in people who are obese and at high
risk.
Insulin-like growth factor-1
and diabetes
Although GH has many actions of its
own, most of its growth-promoting
activities are mediated through the
generation of insulin-like growth
factor-1 (IGF-1).This hormone has
many similarities to insulin both in
structure and in function, including a
rapid reduction in blood glucose
levels. Interestingly, before IGF-1 was
discovered, it was observed that
blood had more insulin-like activity
than could be explained by the
insulin concentration alone. This
phenomenon was termed 'non- >>
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The dawn phenomenon is experienced by some people with diabetes.
It is a significant rise in early morning blood sugar levels before
breakfast. The dawn phenomenon refers to increased glucose
production by the liver and insulin insensitivity brought on by the
release of counter-regulatory hormones such as growth hormone in the
early-morning hours before waking. It is associated with poor control
of blood sugar.
Ketoacidosis is a state of extreme insulin deficiency which is
aggravated by the resulting high blood sugar (hyperglycaemia),
dehydration, and an abnormal increase in the acidity of the body's
fluids. It is a severe acute complication of diabetes resulting from
severe insulin deficiency and an increase in glucagon concentration.
The acidosis is caused by the breakdown of the body's fat stores, which
leads to increased levels of fatty acids. Glucagon accelerates the
oxidation of the fatty acids producing excess ketone bodies (ketosis).
suppressible insulin-like activity'
(NSILA) and IGF-1 was subsequently
shown to be responsible for it.
The major source of IGF-1 in the
circulation is the liver; and insulin
plays a major role in controlling the
production of IGF-1 by the liver.The
amount of insulin reaching the liver
is reduced in people with Type 1
diabetes, even in situations where
there is intensive subcutaneous
insulin treatment. As a
consequence, blood IGF-I
concentrations are reduced in
people who have diabetes.
Interestingly, when insulin therapy is
given directly into the abdominal
cavity by an implantable pump, liver
insulin levels increase and there is
near-normalization of IGF-1
concentrations.
As IGF-1 is important in controlling
pituitary GH secretion, low IGF-I
levels may also explain the increased
GH secretion in Type I diabetes. By
reducing GH secretion, normalizing
(
)
24
Future  D i rec t ions
IGF-I may therefore lead to
improved glucose control both
directly and indirectly.
Clinical trials of IGF-1
When IGF-1 is given to people
with Type 1 diabetes, there is an
improvement in blood glucose
control and a reduction in the
insulin dose required to maintain
normal glucose control. Similar
results, together with a reduction
in fat mass, are seen in people
with Type 2 diabetes who receive
larger doses of IGF-1.
The major limitation to the use
of IGF-1 has been the significant
side effects, including jaw ache,
muscle and joint pains, headache
and swelling of the optic nerve
behind the eye. Consequently,
IGF-1 was withdrawn from
development as an adjunct to
treatment in diabetes.The exact
cause of these side effects
remains unknown. Under normal
conditions, however, over 99% of
IGF-1 is bound  to a family of
IGF-binding proteins. It has been
postulated that the side effects
are caused by the post-injection
unbound IGF-I.
A combination of 
IGF-1 and IGFBP-3
produced a
reduction in insulin
doses and fasting
blood sugar levels
with minimal side
effects.
More recently, a combination of
IGF-1 and IGFBP-3, the major
circulating IGF-binding protein,
has become available. Promising
early clinical trials have been
performed with this compound.
Over a 2-week period, there was
a reduction in insulin doses and
fasting blood sugar levels in both
Type 1 and Type 2 diabetes.
Notably different from previous
studies with IGF-1 alone, this was
achieved with minimal side
effects.2, 3
IGF-1 has also been used in a
number of rare conditions (when
there is extreme insulin
insensitivity because of
abnormalities in the insulin
receptor) to prevent
ketoacidosis and maintain
glucose control. Unfortunately, as
the doses of IGF-1 needed are
high, so is the rate of side effects.
Conclusions
There are abnormalities in both
GH and IGF-1 in people with
diabetes and this contributes to
both the metabolic disturbance
and the susceptibility to
complications. GH may have
potential benefits for people with
abdominal obesity who are at high
risk of Type 2 diabetes. Treatment
with IGF-1 results in improved
diabetic control but its use has
been limited by side effects. More
recently, the combination of IGF-1
and IGFBP-3 has been shown to
lower glucose concentrations but
without these side effects. Further
work will be needed to confirm
the safety and efficacy of this
compound.
` Richard Holt
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